Antidepressant treatments in children and adolescents: II. Anxiety, physical, and behavioral disorders.
Part II of this review critically evaluates antidepressants' (AD) efficacy in children and adolescents with anxiety, physical, and behavioral disorders as well as AD's side-effect spectrum. AD are administered increasingly to youths with specific anxiety syndromes phenomenologically paralleling those in adults which are responsive to AD (e.g., panic, obsessive-compulsive disorders). While several trials have not substantiated earlier theoretical considerations suggesting their usefulness in separation anxiety, their recent success in ameliorating obsessive-compulsive symptoms is encouraging. Systematic drug treatment studies however are limited because of the common overlap of anxiety syndromes with each other and other prominent psychiatric disturbances. More consistent benefits with AD are seen in the physical (e.g., enuresis, bulimia nervosa) and behavioral disorders (e.g., attention deficit-hyperactivity disorder). The wide-ranging benefits of AD in nonaffective disorders suggest AD are more appropriately viewed as broad spectrum pharmacotherapeutics.
Division of Child & Adolescent Psychiatry, Medical College of Pennsylvania/Eastern Pennsylvania Psychiatric Institute, Philadelphia 19129.
P J
PJ
Ambrosini
M D
MD
Bianchi
H
H
Rabinovich
J
J
Elia
D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D002032:Bulimia / Q000188:drug therapy*; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy*; D002675:Child, Preschool; D002997:Clomipramine / Q000627:therapeutic use; D004775:Enuresis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D012640:Seizures / Q000139:chemically induced; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D002997:Clomipramine; D017367:Selective Serotonin Reuptake Inhibitors